Abstract
In 15 patients with rheumatoid arthritis (RA) (n = 13) or psoriatic arthritis (PsA) (n = 2) p-homocysteine and erythrocyte folate (erc-FA) were measured before start of methotrexate (MTX ) treatment, after 4 weeks of MTX treatment (median 10 mg per week), and after further 4 weeks of treatment with MTX (median 12.5 mg per week) supplemented with folic acid (FA) (15 mg per week). Mean p-homocysteine were 12.3 - 3.4 w mol/l, 14.6 - 5.8 w mol/l (p < 0.05) and 10.3 - 3.0 w mol/l (p < 0.01) respectively. P-homocysteine concentrations were negative correlated to erc-FA after 4 weeks (rho- 0.58; p< 0.05). It is concluded that treatment with MTX induces a significant rise in p-homocysteine that is neutralised by FA supplementation. Supplementation with FA from the start of MTX treatment is recommended considering the increased risk of cardiovascular disease that is associated with elevated concentrations of p-homocysteine.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
